Wednesday, June 19, 2013

Ohr’s squalamine eye drops gain media exposure

Ohr’s squalamine eye drops gain media exposure

June 19, 2013 by · Leave a Comment 

Tweet Ohr Pharmaceutical’s (NASDAQ:OHRP) squalamine eye drops, which are in Phase 2 testing for the wet form of AMD, the leading cause of blindness in seniors, were featured in an article in the Daily Mail’s online publication, mail online. The article discusses squalamine’s ability to prevent the abnormal growth of blood vessels at the back [...]

Ladenburg starts Stemline Therapeutics at buy

Ladenburg starts Stemline Therapeutics at buy

June 18, 2013 by · Leave a Comment 

Tweet Ladenburg Thalmann has initiated coverage of Stemline Therapeutics (NASDAQ:STML) with a “buy” rating and $36 price target, saying that at current prices, it views Stemline as an “attractive investment opportunity with significant upside potential.” The stock closed at $20.58 on Monday and jumped to a 52-week of $21.84 after the opening on Tuesday. “Stemline [...]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including [...]

NovaBay supports legislation on antibiotic resistance

NovaBay supports legislation on antibiotic resistance

June 17, 2013 by · Leave a Comment 

Tweet NovaBay Pharmaceuticals (NYSE:NBY) announced its support for legislation by U.S. Rep. Jim Matheson to attack the growing crisis of antibiotic resistance. “NovaBay believes that there must be a multi-pronged, comprehensive approach to combating antimicrobial resistance and Rep. Matheson’s bill is an important contribution,” Dr. Ron Najafi, chairman and CEO, said in a statement. “We’ve [...]

William Blair start Portola Pharma at outperform

William Blair start Portola Pharma at outperform

June 17, 2013 by · Leave a Comment 

Tweet William Blair & Co. has initiated coverage of Portola Pharmaceuticals (NASDAQ:PTLA) with an “outperform” rating. The stock closed at $20.79 on Friday. Portola’s lead compound, Betrixaban, is an anticoagulant that inhibits factor Xa, a protein involved in blood coagulation. It is currently in Phase 3 clinical trial, known as APEX, and to date, has [...]

Eli Lilly exercises rights to Transition Therapeutics’ TT-401

Eli Lilly exercises rights to Transition Therapeutics’ TT-401

June 17, 2013 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) said that Eli Lilly (NYSE:LLY) has exercised its option to assume all development and commercialization rights to the Type 2 diabetes drug candidate TT-401, resulting in a $7-million milestone payment to Transition. Lilly and Transition also amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly [...]

Synthetic Biologics to host MS investor day

Synthetic Biologics to host MS investor day

June 14, 2013 by · Leave a Comment 

Tweet Synthetic Biologics (NYSE MKT:SYN) will host a multiple sclerosis-estriol investor day on June 25 from 9:00 a.m. to 11:00 a.m. at the InterContinental New York Barclay Hotel in New York. Keynote speaker, Dr. Rhonda Voskuhl, will join Synthetic Biologics’ executive management remotely for the presentations. Dr. Voskuhl is professor, Department of Neurology, Jack H. [...]

Cantor starts Ensign Group at buy

Cantor starts Ensign Group at buy

June 14, 2013 by · Leave a Comment 

Tweet Cantor Fitzgerald has initiated coverage of Ensign Group (NASDAQ:ENSG) with a “buy” rating and $40 price target. The stock closed at $35.86 on Thursday. “Ensign is a leading provider of skilled nursing and rehabilitation services that is growing rapidly through acquisitions, development and the addition of services required to care for patients recovering from [...]

Ohr Pharma to begin trading on NASDAQ tomorrow

Ohr Pharma to begin trading on NASDAQ tomorrow

June 12, 2013 by · Leave a Comment 

Tweet Ohr Pharmaceutical (OTCQB:OHRPD) is expected to begin trading on the NASDAQ Capital Market at the opening on June 13 under the ticker symbol, OHRP. The common stock will continue to trade on the Over-the-Counter Bulletin Board until the market close on June 12. In honor of the listing, the company will ring the opening bell at the NASDAQ [...]

Lifeline Skin Care expands Asian distribution

Lifeline Skin Care expands Asian distribution

June 11, 2013 by · Leave a Comment 

Tweet International Stem Cell (OTCQB:ISCO) subsidiary, Lifeline Skin Care, has signed distribution agreements to sell its stem cell skin care products in both Thailand and Viet Nam, with launches set for this summer. Complementing Lifeline’s current distribution relationship in China, the company said the two new agreements demonstrate Lifeline’s commitment to capitalize on the enormous opportunities in the Asian market. Throughout [...]

Next Page »